Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Australia: Innovative Biotech Approach to Bladder Cancer

Getting your Trinity Audio player ready...

In Queensland, a pioneering diagnostic and treatment strategy for bladder cancer is poised to enter a clinical trial, propelled by a startup founded on technology developed by Mater Research and University of Queensland Honorary Professor John Hooper’s innovative approach. The startup secured a substantial AU$ 950,500 CUREator grant from the Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) programme.

Image credits: University of Queensland

Bladder cancer, afflicting approximately 570,000 individuals globally each year, often progresses to an advanced and aggressive stage. Professor Hooper elucidated that their novel technology represents a theranostic advancement, seamlessly integrating diagnostic imaging with precisely targeted therapy.

By enhancing the visibility of cancerous tumour cells on scans, the approach facilitates informed, targeted, and personalised treatments. The technology’s efficacy hinges on its ability to detect a specific protein, potentially revolutionising the diagnosis and treatment of bladder cancer while offering promise for other malignancies such as ovarian, breast, colorectal, prostate, and lung cancer.

The genesis of this transformative technology traces back to Professor Hooper’s extensive research dating back to 2001, culminating in a collaborative effort with the Scripps Research Institute and CSIRO. Noteworthy collaborators include esteemed professionals like Associate Professor Paul Thomas, Associate Professor Matt Roberts, Dr. Niara Oliveira, Dr. Admire Matsika, and Professor Ian Vela from institutions including Royal Brisbane and Women’s Hospital, and Mater Cancer Care Centre. Dr. Roberts emphasised the inadequacies of current scanning and imaging modalities in detecting bladder cancer, underscoring the potential of the protein target to serve as a beacon for precise identification and treatment.

The CUREator scheme, in tandem with its commitment to advancing medical innovation, allocated an additional AU$500,000 to Frontier Inflammasome Therapeutics, bolstering its preclinical endeavours to develop a groundbreaking therapy for inflammatory conditions lacking effective treatments. This venture unfolds within UniQuest’s Queensland Emory Drug Discovery Initiative, in collaboration with Professor Kate Schroder’s Inflammasome Lab at UQ’s Institute for Molecular Bioscience, exemplifying the collaborative spirit driving medical innovation.

UniQuest, the commercialisation arm of the University of Queensland, emerges as a pivotal catalyst in nurturing and propelling both OncoStrike Biopharma and Frontier Inflammasome Therapeutics. The comprehensive support provided by UniQuest underscores its commitment to fostering the translation of cutting-edge research into tangible solutions with significant commercial potential.

One supporter of burgeoning biotechnological endeavours has been instrumental in shepherding 42 clinical and preclinical stage companies through the CUREator ESTAC stream since 2022. Through strategic investment and unwavering support, the supporter continues to spearhead the advancement of promising Australian initiatives, positioning them on a trajectory toward commercial success and societal impact.

Queensland emerges as a beacon of innovation in the realm of medical research and biotechnology, propelled by collaborative efforts between academia, industry, and government initiatives. The convergence of pioneering technologies, visionary leadership, and strategic investment heralds a new era of transformative advancements in healthcare, promising hope and improved outcomes for patients grappling with complex and challenging medical conditions.

The global biotechnology sector, valued at US$1.55 trillion in 2023, is anticipated to experience a robust compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, propelled by technological advancements. Government support, including initiatives aimed at enhancing regulatory frameworks and streamlining approval processes, coupled with improvements in reimbursement policies, fuels market expansion.

The rise of personalised medicine and the proliferation of orphan drug formulations serve as catalysts, fostering innovation and driving the emergence of cutting-edge technology companies within the biotechnology sphere. This convergence of factors not only accelerates the adoption of biotechnological solutions but also creates lucrative opportunities for emerging tech ventures to thrive and contribute to the sector’s growth trajectory.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.